Nuveen
IPSC icon

Nuveen’s Century Therapeutics IPSC Stock Holding History

Nuveen’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
+163,592
New +$374K ﹤0.01% 3370
2025
Q2 		– Sell
-157,311
Closed -$74.9K – 3329
2025
Q1 		$74.9K Hold
157,311
– – ﹤0.01% 3241
2024
Q4 		$159K Buy
157,311
+51,661
+49% +$70.3K ﹤0.01% 3244
2024
Q3 		$181K Hold
105,650
– – ﹤0.01% 3242
2024
Q2 		$269K Buy
105,650
+45,611
+76% +$144K ﹤0.01% 3172
2024
Q1 		$251K Hold
60,039
– – ﹤0.01% 3134
2023
Q4 		$199K Buy
60,039
+1,087
+2% +$1.98K ﹤0.01% 3217
2023
Q3 		$118K Hold
58,952
– – ﹤0.01% 3111
2023
Q2 		$186K Hold
58,952
– – ﹤0.01% 3104
2023
Q1 		$205K Sell
58,952
-1,087
-2% -$4.77K ﹤0.01% 2986
2022
Q4 		$308K Sell
60,039
-15,742
-21% -$149K ﹤0.01% 2981
2022
Q3 		$750K Buy
75,781
+26
+0% +$274 ﹤0.01% 2850
2022
Q2 		$636K Buy
75,755
+50,765
+203% +$498K ﹤0.01% 2955
2022
Q1 		$290K Buy
24,990
+8,289
+50% +$110K ﹤0.01% 3129
2021
Q4 		$223K Hold
16,701
– – ﹤0.01% 3224
2021
Q3 		$420K Buy
+16,701
New +$452K ﹤0.01% 3201

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Nuveen's IPSC Position: Q2 2026 in Review

Nuveen opened a new position in Century Therapeutics (IPSC) in Q2 2026: 163,592 shares worth $401K. The stake represents ﹤0.01% of the portfolio and ranks #3370 among its holdings. This is a return to the name: Nuveen previously reported a position in IPSC as recently as Q1 2025.

Nuveen first reported a position in IPSC in Q3 2021 and has held it in 16 quarters since. The position peaked at $750K in Q3 2022. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Nuveen held 163,592 shares of Century Therapeutics worth $401K as of Q2 2026.
  • Century Therapeutics was a new Nuveen position in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3370 holding.
  • Nuveen first reported a position in Century Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Nuveen's Century Therapeutics position peaked at $750K in Q3 2022.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.